New obesity drug HRS-5817 enters human safety testing

NCT ID NCT07238647

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests the safety of a single dose of HRS-5817 in 40 obese adults aged 18-55. Participants receive either the drug or a placebo by injection. The study monitors side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HRS-5817

What this could lead to

If successful, this could lead to a new weight-loss drug that helps control obesity.

What could go wrong

This is a very early, small study focused on safety, not effectiveness. The drug may not work or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Linear

    Perth, Western Australia, 6027, Australia